Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX), another biotech, the company is making headway with a gene therapy for Duchenne muscular dystrophy (DMD), the condition that's Sarepta's focus.
Does an upcoming new player on the scene pose a big-enough threat to Sarepta to justify selling the stock today? The answer is a bit more complicated than merely "no," so let's dive in and clarify the issue.
Regenxbio's gene therapy program is called RGX-202, and it could provide a measure of long-lasting relief to patients with DMD. The concept of RGX-202, as well as Sarepta's Elevidys therapy, is to replace the dysfunctional copies of a patient's disease-related genes with synthetically designed functional versions, such that when those genes are expressed by cells, the correct protein is produced rather than a dysfunctional version. Then the patient's symptoms, like muscle weakness and mobility issues, hopefully start to abate.
Source Fool.com
Sarepta Therapeutics Stock
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 8.02% for Sarepta Therapeutics compared to the current price of 120.35 €.
